Perspectum Diagnostics

Oxford, United Kingdom All United Kingdom companies → — Founded 2012

Biotech / Drug Discovery Imaging AI Specialist

Gastroenterology Radiology

Gastroenterology AI Radiology & Imaging AI

Series C

Claim this company

Products

MRCP+

Perspectum

Gastroenterology AI

MRCP+ by Perspectum Diagnostics is an AI-powered advanced biliary visualization software that enhances MRCP images to provide quantitative assessment and improved 3D visualization of the biliary tree and pancreatic duct, aiding in the diagnosis and monitoring of pancreatobiliary diseases like Primary Sclerosing Cholangitis (PSC).

Not specified

See all 1 product →

About Perspectum Diagnostics

Perspectum Diagnostics is a precision health company that originated as a spin-out from the University of Oxford in 2012. The company specializes in developing non-invasive medical imaging software and AI-powered diagnostics to provide quantitative clinical insights for chronic metabolic diseases, multi-organ pathologies, and cancer. Their proprietary technology, such as the flagship product LiverMultiScan, utilizes multiparametric MRI to quantify and characterize liver tissue, measuring fat, iron, fibrosis, and inflammation. This aims to offer a less invasive and more comprehensive alternative to traditional liver biopsies, which are costly, painful, and limited in scope.

Perspectum’s vision is to empower patients and clinicians through advanced imaging and genetics, enabling earlier detection, diagnosis, and targeted treatment of chronic systemic diseases. Their software-as-a-service (SaaS) platform, the Perspectum Portal, delivers these solutions globally to approximately 350 locations, leveraging existing MRI hardware. The company also operates an imaging-focused Contract Research Organization (CRO) to support biopharmaceutical firms in drug development for liver and metabolic diseases. They are committed to continued clinical development across a spectrum of conditions, including NASH, viral hepatitis, liver cancer, autoimmune diseases, biliary conditions, long COVID, and diabetes.

Focus Areas

medical imaging software AI-powered diagnostics quantitative biomarkers liver disease metabolic diseases multi-organ assessment cardiometabolic conditions cancer long COVID diabetes

Business Intelligence

Technology

cloud-based software suite, AI algorithms, multiparametric MRI analysis, SaaS (Software-as-a-Service) platform (Perspectum Portal)

What Physicians Need to Know

Liver Disease & Metabolic Diseases

Perspectum specializes in non-invasive diagnostics for liver and metabolic diseases, including fatty liver disease (NAFLD/NASH), iron overload (hemochromatosis), and autoimmune liver diseases. Their flagship product, LiverMultiScan, uses multiparametric MRI to quantify liver fat, iron, and fibro-inflammation, offering a comprehensive assessment of liver health. They also offer solutions for cardiometabolic conditions and body composition analysis for drug development.

Multi-organ Pathology & Long COVID

Perspectum provides a multi-organ MRI assessment platform called CoverScan, which quantifies tissue characteristics from up to six different organs (heart, liver, lungs, kidneys, pancreas, and spleen) in a single, non-contrast MRI scan. This technology supports clinical decision-making for multi-systemic diseases like Long COVID and insulin resistance.

Cancer & Drug Development Biomarkers

The company develops imaging biomarkers for oncology solutions and supports drug development across various therapeutic areas. They have received an FDA grant to evaluate a novel biomarker for rare diseases, specifically primary sclerosing cholangitis (PSC), aiming to revolutionize monitoring and treatment. Their technologies provide standardized biomarkers for patient characterization and assessing treatment response in clinical trials.

AI-Driven Solutions & Quantitative Imaging

Perspectum leverages AI-powered diagnostics and quantitative imaging to analyze MRI data and extract biomarkers. Their software converts MRI data into objective measurements of tissue characteristics, aiming to replace invasive procedures like biopsies. They are collaborating with GE Healthcare and the University of Oxford to develop scalable AI solutions for diagnosing liver disease with MRI, including early detection of iron overload.

Digital Health & Diagnostics

Perspectum offers cloud-based imaging analytics and reporting portals, delivering diagnostic reports to referring doctors, often within 24 hours. Their digital health solutions aim to improve access to state-of-the-art healthcare and empower patients and clinicians with a greater understanding of disease for earlier diagnosis and targeted treatment.

Physician Tip

Perspectum's non-invasive MRI-based solutions, such as LiverMultiScan and CoverScan, offer quantitative, objective data on organ health, reducing the need for invasive biopsies. The rapid turnaround of comprehensive reports (within 24 hours for LiverMultiScan) provides timely insights for diagnosis, treatment planning, and monitoring disease progression. Their AI-driven analytics help in interpreting complex imaging data, supporting more informed clinical decisions and personalized patient care across various chronic and multi-systemic diseases. The integration with existing MRI hardware makes their solutions easily adoptable into current clinical workflows.

Perspectum's software services are designed to integrate with existing MRI infrastructure, requiring compatible scanners. They collaborate with companies like GE Healthcare to develop scalable AI solutions and have partnered with Nuance Communications to scale access to their AI-enabled integrated digital care platforms within Nuance's Precision Imaging Network, connecting radiologists and providers for secure sharing of AI insights. Their cloud-based platform facilitates the delivery, review, and distribution of MRI-derived analytics and diagnostic reports.

Products by Perspectum Diagnostics

1 product in the directory

MRCP+

Perspectum

Gastroenterology AI

Not specified

What the Web Says

Perspectum Diagnostics is an Oxford-based medical solutions company specializing in advanced imaging solutions for chronic systemic diseases, particularly liver disease. Their flagship product, LiverMultiScan, is a non-invasive MRI-based tool that quantifies and characterizes liver tissue, aiming to reduce the need for liver biopsies and improve patient care. While the company's products are recognized for their scientific innovation and potential for cost-effectiveness in healthcare, employer reviews indicate significant issues with management, work-life balance, and company culture.

Overall: Mixed

Strengths

Scientifically innovative products for non-invasive diagnostics.
LiverMultiScan can significantly reduce the need for liver biopsies and offer cost savings.
Products aim to improve clinical decision-making, patient safety, and experience.
Focus on integrated data intelligence and a patient-first approach.
Good company perks like gym discounts and private health insurance (based on older reviews).
Opportunities for internships and a generally nice culture among colleagues (based on some reviews).

Limitations

Poor management.
Toxic company culture.
Lack of work-life balance.
Low job security and advancement opportunities.
Inexperienced management that may not follow rules or regulations.
Some senior management members are unwilling to provide guidance or tasks to interns.

Based on reviews from: Indeed.com, PharmaTimes, AuntMinnie, Medical Technology Enterprise Consortium (MTEC), Care Quality Commission (CQC)

Last updated: 2026-10-19

Videos

News, demos, and interviews about Perspectum Diagnostics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Perspectum Diagnostics →

View all on YouTube

Press & Coverage

Perspectum

Perspectum Appoints Warren Cresswell as Chief Executive Officer

Perspectum announced the appointment of Warren Cresswell as Chief Executive Officer, effective September 15, 2026.

2026-09

Perspectum

FDA Grants Clearance to Perspectum's CoverScan – A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan

Perspectum received FDA 510(k) clearance for CoverScan, a noninvasive multiparametric advanced cloud-based software suite for comprehensive assessment of six organs.

2022-05

Perspectum

Perspectum Completes $36 Million First Close of Series C Funding Led by Oppenheimer Holdings

Perspectum announced the first close of its Series C funding round, securing $36 million led by Oppenheimer Holdings, bringing total funding to approximately $120 million.

2023-01

Perspectum

Perspectum Closes $36M Financing Round co-led by Blue Venture Fund and HealthQuest Capital

Perspectum completed a $36 million financing round co-led by Blue Venture Fund and HealthQuest Capital, aimed at commercializing LiverMultiScan and expanding its CRO business.

2020-04

Perspectum

LiverMultiScan™ Receives FDA 510(k) Clearance for Version 2 of Medical Device

Perspectum Diagnostics announced FDA 510(k) clearance for LiverMultiScan, expanding its compatibility with more MRI systems for non-invasive liver assessment.

2017-11

PR Newswire

Perspectum Diagnostics Announces FDA Clearance for LiverMultiscan MR Imaging Device

Perspectum Diagnostics received FDA clearance for LiverMultiScan, an imaging test designed to detect early-stage liver disease using a non-invasive 15-minute MRI scan.

2015-11

PharmaTimes

Company focus: Perspectum Diagnostics

This article discusses how Perspectum Diagnostics, a University of Oxford spin-out, is using AI and its LiverMultiScan technology to address challenges in non-alcoholic fatty liver disease (NAFLD).

2018-03

Medical Device Network

Perspectum Diagnostics: the biggest start-up you've never heard of

This feature highlights Perspectum Diagnostics as a rapidly growing medtech company and the University of Oxford's largest spinout, focusing on its LiverMultiScan technology and its application in assessing COVID-19's long-term organ impact.

2020-07

Frequently Asked Questions

What specific liver and metabolic diseases do Perspectum's AI-driven quantitative imaging solutions help diagnose and monitor?

Perspectum's solutions, such as LiverMultiScan, are designed to quantify liver fat, iron, and fibrosis, aiding in the diagnosis and monitoring of conditions like Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), and hemochromatosis. This quantitative data supports precision medicine approaches by providing objective measures of disease progression and treatment response.

How do Perspectum's technologies contribute to cancer detection and multi-organ pathology assessment, particularly in the context of precision medicine and drug development?

Perspectum's quantitative imaging can identify early markers of multi-organ pathology, which can be crucial in cancer patients for assessing treatment toxicity or metastatic spread. By providing precise, objective biomarkers, their technology supports drug development by offering endpoints for clinical trials and enabling personalized treatment strategies.

What role does Perspectum play in addressing Long COVID, and how do their digital health and diagnostic tools assist in managing this complex condition?

Perspectum offers solutions like CoverScan, which provides a comprehensive multi-organ assessment to identify and quantify organ damage associated with Long COVID. This digital health tool helps physicians understand the extent of post-viral complications, guiding personalized management plans and supporting research into the long-term effects of the virus.

What is the regulatory compliance status of Perspectum's diagnostic products, and what kind of support and training can healthcare providers expect?

Perspectum's diagnostic products, including LiverMultiScan, are CE marked and FDA cleared, ensuring they meet stringent regulatory standards for clinical use. Healthcare providers can expect comprehensive support, including training on product usage, data interpretation, and integration into existing clinical workflows, to maximize the utility of their AI-driven solutions.

How does Perspectum's pricing model work for their quantitative imaging services, and what are the options for integrating their solutions into a hospital or clinic's existing infrastructure?

Perspectum typically offers flexible pricing models that can include per-scan fees, subscription services, or enterprise-wide licenses, depending on the volume and specific needs of the institution. Their solutions are designed for seamless integration with existing MRI scanners and PACS systems, often through secure cloud-based platforms, minimizing the need for significant infrastructure changes.

What partnerships does Perspectum have with pharmaceutical companies or research institutions, and how do these collaborations advance drug development biomarkers and precision medicine?

Perspectum actively collaborates with leading pharmaceutical companies and academic research institutions to develop and validate novel imaging biomarkers for drug development. These partnerships accelerate the identification of new therapeutic targets, optimize clinical trial design, and ultimately bring more effective precision medicine solutions to patients.

Given the rapid evolution of AI and digital health, what is Perspectum's strategy for maintaining company stability and ensuring the long-term viability and innovation of its diagnostic offerings?

Perspectum maintains stability through continuous investment in R&D, a strong intellectual property portfolio, and strategic partnerships that expand their market reach and product pipeline. Their commitment to innovation in AI-driven quantitative imaging and digital health ensures they remain at the forefront of diagnostic advancements, adapting to evolving healthcare needs and regulatory landscapes.

Related Companies

Suggest an Edit → | Report an issue